Richard Goldberg M MD

Richard Goldberg M MD
ProfessorCollege of Medicinegoldberg.218@osu.edu
Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:Fax:
  • Translational Therapeutics

Research Description

Dr. Goldberg's research focuses on clinical studies in patients with GI cancers (principally colorectal), translational studies with laboratory collaborators on biologic specimens from patients with cancer, development of new cancer drugs and drug combinations, and clinical trials methodology.

Current Publications

  • Sargent DJ, Eckhardt SG, Eng C, Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RMAssociation of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program.J Clin Oncol in press 7/7/2014
  • McRee AJ, Davies JM, Sanoff HG, Goldberg RM, Bernard S, Claire Dees E, Keller K, Ivanova A, O'Neil BHA phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.Cancer Chemother Pharmacol 74 117-23 7/1/2014
  • Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in OncologyPatient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147.J Natl Cancer Inst 106 7/1/2014
  • Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RM, Haraldsdottir S, Hampel H, Wei L, Wu CProstate cancer incidence in males with Lynch syndrome.Genet Med 16 553-7 7/1/2014
  • O'Neil BH, Cainap C, Van Cutsem E, Gorbunova V, Karapetis CS, Berlin J, Goldberg RM, Qin Q, Qian J, Ricker JL, Fischer J, McKee MD, Carlson DM, Kim TWRandomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer.Clin Colorectal Cancer in press 6/23/2014
  • Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Sargent DJ, Alberts SR, Alliance for Clinical Trials in OncologyComparison of FOLFIRI with or without cetuximab in patients with resected stage iii colon cancer; NCCTG (Alliance) intergroup trial N0147.Clin Colorectal Cancer 13 100-9 6/1/2014
  • Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in OncologyKRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance).Clin Cancer Res 20 3033-43 6/1/2014
  • Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in OncologyCpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer.Gastroenterology in press 5/21/2014
  • Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod HGermline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.PLoS One 9 e94727 1/1/2014
  • Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI, Alliance for Clinical Trials In Oncology, Nixon AB, Pang H, Starr MD, Friedman PNPrognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).Clin Cancer Res 19 6957-66 12/15/2013
  • Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RMRandomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.Cancer 119 4223-30 12/15/2013
  • Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB 3rd, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, Alliance for Clinical Trials in OncologyPredictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.J Natl Cancer Inst 105 1789-98 12/4/2013
  • Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MMUGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.Invest New Drugs 31 1559-67 12/1/2013
  • Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Bertagnolli MM, Saltz LBAssociation of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.Clin Cancer Res 19 5777-87 10/15/2013
  • Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SRPrognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.J Clin Oncol 31 3664-72 10/10/2013
  • Sanoff HK, Goldberg RMHow we treat metastatic colon cancer in older adults.J Geriatr Oncol 4 295-301 10/1/2013
  • Haraldsdottir S, Wu C, Bloomston M, Goldberg RMWhat is the optimal neo-adjuvant treatment for liver metastasis?Ther Adv Med Oncol 5 221-34 7/1/2013
  • Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BHA two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.Am J Clin Oncol 36 250-3 6/1/2013
  • Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JAComparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.Clin Colorectal Cancer 12 95-102 6/1/2013
  • Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MMBiologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.J Clin Oncol 31 1775-81 5/10/2013
  • Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) GroupBody mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.Cancer 119 1528-36 4/15/2013
  • Wu C, Goldberg RMColorectal cancer in 2012: Revisiting landmark trials and identifying new therapies.Nat Rev Clin Oncol 10 71-2 2/1/2013
  • Humblet Y, Bouché O, Mineur L, Barone C, Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, CORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet 381 303-12 1/26/2013
  • Wu C, Goldberg RMManaging choices for older patients with colon cancer: adjuvant therapy.Am Soc Clin Oncol Educ Book 1/1/2013
  • Bekaii-Saab T, Goldberg RMFOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?Oncologist 18 487-9 1/1/2013
  • Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Gomi K, Lee PH, Gramont A, Rothenberg ML, André T, Brienza S, Goldberg RMAnalysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.Cancer Med 1 198-206 10/1/2012
  • Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag DComparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.Cancer 118 4309-20 9/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu